EARLY BREAST CANCER
Clinical trials for EARLY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new EARLY BREAST CANCER trials appear
Sign up with your email to follow new studies for EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a diabetes drug slow breast cancer growth?
Disease control Not yet recruitingThis phase 2 trial investigates whether tirzepatide, a drug used for weight loss and diabetes, can slow tumor growth in people with early-stage hormone-receptor-positive breast cancer. Participants receive tirzepatide alone, the standard hormone therapy letrozole alone, or both t…
Matched conditions: EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New daily pill could help breast cancer patients who Can't tolerate standard hormone drugs
Disease control Not yet recruitingThis phase 3 trial is testing a daily pill called giredestrant in 300 people with ER+/HER2- early breast cancer who had to stop standard aromatase inhibitors due to side effects. The study will track how well patients stick with the treatment, their quality of life, and any side …
Matched conditions: EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Gene test may spare young breast cancer patients from chemo
Disease control Not yet recruitingThis study looks at whether a genetic test (Prosigna®) can help decide if younger women with early, hormone-sensitive breast cancer need chemotherapy. About 3380 premenopausal women will either get standard treatment (chemo plus hormone therapy) or a treatment plan based on the t…
Matched conditions: EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug duo aims to wipe out breast cancer before surgery
Disease control Not yet recruitingThis study tests a new drug combination (SHR-A1811 plus pertuzumab) given before surgery to women with early or locally advanced HR-positive, HER2-positive breast cancer. The goal is to see if this treatment can eliminate all cancer cells in the breast and lymph nodes by the time…
Matched conditions: EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Homeopathic shot may shield cancer patients from chemo nerve pain
Prevention Not yet recruitingThis phase 3 trial tests whether a homeopathic remedy called Stibium metallicum praeparatum 6x can prevent or reduce nerve damage caused by the chemotherapy drug paclitaxel. The study will include 120 breast cancer patients who will receive either the remedy or a placebo injectio…
Matched conditions: EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: University of Bern • Aim: Prevention
Last updated Jun 27, 2026 07:59 UTC
-
Which Follow-Up treatment works best for HER2+ breast cancer? large study aims to find out
Knowledge-focused Not yet recruitingThis study looks back at medical records of 2000 women with HER2-positive early breast cancer who still had cancer after initial treatment. Researchers want to see which follow-up drug regimen—trastuzumab plus pertuzumab or T-DM1—leads to better long-term outcomes. The goal is to…
Matched conditions: EARLY BREAST CANCER
Sponsor: Hebei Medical University Fourth Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Breast cancer study to track Real-World use of newer pills
Knowledge-focused Not yet recruitingThis study will follow 81 people with early-stage, hormone-positive breast cancer who are at high risk of the cancer coming back. Researchers want to see how often patients take their prescribed CDK4/6 inhibitor pills (abemaciclib or ribociclib) alongside standard hormone therapy…
Matched conditions: EARLY BREAST CANCER
Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
100,000 breast cancer patients to be studied for recurrence patterns
Knowledge-focused Not yet recruitingThis study will analyze medical records from 100,000 people in Korea who had early-stage hormone receptor-positive, HER2-negative breast cancer and received surgery followed by other treatments. The goal is to see how often the cancer comes back and what factors might affect that…
Matched conditions: EARLY BREAST CANCER
Sponsor: Samsung Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC